Questions · Indexed
GHK-Cu, Answered
Twenty-two questions about the copper tripeptide, each answered directly from the published record and cited where the answer carries a number.
What is GHK-Cu and how does it work?
GHK-Cu is the glycyl-L-histidyl-L-lysine copper(II) complex, a copper-binding tripeptide that acts as both a copper chaperone and a pleiotropic signaling molecule. In fibroblast cultures it stimulates collagen synthesis at picomolar-to-nanomolar concentrations, with onset between 10⁻¹² and 10⁻¹¹ M [1], and it rebalances matrix metalloproteinases against their TIMP inhibitors while broadly shifting gene expression toward repair [2][7].
What is the difference between GHK and GHK-Cu?
GHK is the free tripeptide (MW 340.38); GHK-Cu is its copper(II) chelate (MW 402.92) [3]. Copper coordination is required for most documented tissue-repair activity — the free peptide does not reproduce GHK-Cu's stimulation of MMP-2 in fibroblast cultures, so the chelate carries the effect, not the bare peptide [7].
What does a copper peptide do for your skin?
In research models GHK-Cu stimulates dermal fibroblast synthesis of collagen, dermatan and chondroitin sulfate, and the proteoglycan decorin [3]. A reviewed figure reports topical GHK-Cu increased collagen production in 70% of treated women, versus 50% for vitamin C and 40% for retinoic acid [3], alongside trial-reported gains in skin density and firmness.
What is the GHK-Cu mechanism of action?
GHK-Cu chaperones copper to enable lysyl-oxidase collagen and elastin cross-linking and SOD-like antioxidant activity, induces MMP-2 with concurrent TIMP upregulation in an effect that requires the copper-bound form [7], and broadly shifts gene expression toward wound-repair, DNA-repair, and antioxidant programs while suppressing NF-κB inflammation [2].
What does a GHK-Cu peptide do?
Across study models GHK-Cu drives matrix remodeling — increasing collagen, elastin, glycosaminoglycans, VEGF, FGF-2, and neurotrophins while suppressing free radicals, TGF-β1, and TNF-α — and chemoattracts repair cells such as macrophages and capillary cells [6]. The direction is balanced remodeling rather than one-way stimulation.
Is GHK-Cu peptide really anti-aging?
The evidence is mechanistic and partly bioinformatic: GHK modulates roughly 31.2% of human genes at a 50%-or-greater change threshold toward repair and antioxidant programs [2], and plasma GHK declines from about 200 ng/mL at age 20 to about 80 ng/mL by 60 [3]. These findings motivate the anti-aging hypothesis but rest largely on in-vitro and Connectivity Map data [2].
Does GHK-Cu actually increase collagen production?
In human fibroblast cultures GHK-Cu stimulated collagen synthesis beginning between 10⁻¹² and 10⁻¹¹ M, peaking near 10⁻⁹ M, independent of any change in cell number — a specific metabolic effect rather than a proliferation artifact [1]. That 1988 dose-response is the foundational collagen result.
Do copper peptides stimulate hair growth?
Preclinically, peptide-copper complexes stimulated hair-follicle activity in C3H mice [9], and in a six-month trial of 45 men a 5-ALA+GHK complex (ALAVAX) increased hair count by 52.6–71.5 versus 9.6 for placebo (p < 0.05) [4] — the strongest controlled human signal, though for a combination rather than pure GHK-Cu.
Does copper peptide regrow hair?
The controlled human data come from the 45-patient ALAVAX trial, where the 50 mg/mL GHK complex produced the largest hair-count gain (+71.5 hairs) over six months with no adverse events [4]; the underlying follicle effects are supported by the C3H-mouse copper-peptide study [9]. It is a single combination-formulation RCT, not pure GHK-Cu monotherapy.
Does copper peptide work for hair growth?
In the published research it does: the ALAVAX 5-ALA+GHK complex significantly outperformed placebo on hair count over six months [4], and animal models show copper peptides stimulate follicle activity [9]. The human evidence is a single combination-formulation RCT, not pure GHK-Cu monotherapy, so the pure-peptide effect is not separately quantified.
How long does GHK-Cu take to regrow hair?
The only controlled human hair trial measured outcomes over six months; the 5-ALA+GHK complex produced statistically significant hair-count increases versus placebo across that window [4]. No shorter validated timeline for pure GHK-Cu exists in the peer-reviewed record, and that six-month figure is a study duration, not a usage schedule.
Is copper a DHT blocker?
The copper-peptide hair research describes a non-androgenic mechanism — dermal-papilla proliferation, angiogenesis, and Wnt/β-catenin-driven anagen entry — rather than DHT inhibition [6]. The ALAVAX trial reported no adverse events [4], and copper-peptide effects in the literature are not framed as 5-alpha-reductase or DHT blockade.
What are the downsides of copper peptides?
Reported concerns include localized hyperpigmentation with some topical applications, a theoretical copper-accumulation risk with prolonged systemic use, low native skin penetration (free GHK clogP −2.24) [15], and incompatibility with vitamin C and low-pH acids [3]. No human copper-toxicity case attributed to GHK-Cu appears in the peer-reviewed record.
How long does it take GHK-Cu to tighten skin?
There is no single validated timeline; the small placebo-controlled facial trials in the literature ran on the order of weeks to a few months and reported improvements in skin density, firmness, and wrinkle depth [3]. These are study durations, not a personal usage schedule.
Is GHK-Cu better than retinol?
The most-cited head-to-head figure reports topical GHK-Cu raised collagen production in 70% of subjects, versus 40% for retinoic acid and 50% for vitamin C [3]. The two work by different mechanisms, and the comparison rests on reviewed clinical figures rather than a single direct trial [3].
What shouldn't be mixed with GHK-Cu?
Strong reducing agents such as ascorbic acid below about pH 3.5 reduce Cu(II) and break the complex, and AHAs, BHAs, and other low-pH actives can destabilize it or compete for copper [3]. Vitamin C serums and low-pH exfoliating acids are therefore the classic incompatibilities in the formulation literature.
Does GHK-Cu affect inflammation?
Yes — in the tissue-remodeling literature GHK-Cu suppresses TNF-α, TGF-β1, free radicals, and NF-κB-driven inflammation [6]. A biotinylated GHK-copper complex also showed antioxidant and antiglycation activity against amyloid-β/acrolein adducts in vitro [14].
Is GHK-Cu safe for long-term use?
Topical Copper Tripeptide-1 is a legal cosmetic ingredient with a long marketed safety record, but there is no validated long-term human safety or pharmacokinetic data for systemic GHK-Cu [3]. The literature flags a theoretical copper-accumulation risk and a hyperpigmentation signal, and all framing here is research-context, not a usage recommendation.
Can GHK-Cu help with wound healing?
Wound repair is one of GHK-Cu's most-studied roles: the tissue-remodeling review documents increased VEGF, FGF-2, collagen, and elastin with suppressed free radicals and TGF-β1 [6], and biomaterial systems — HA hydrogel nanofibers [10], GHK-modified alginate [11], and GHK-Cu-coated scaffolds [12] — accelerated closure and angiogenesis in animal and cell models.
What genes does GHK-Cu affect?
Connectivity Map analyses report GHK modulates about 31.2% of human genes at a 50%-or-greater change threshold (59% up, 41% down), strongly stimulating the ubiquitin-proteasome system (41 genes up, 1 down) plus DNA-repair and antioxidant gene sets [2]. The often-quoted "about 4,000 genes" figure is an extrapolation of the roughly 2,100 genes at that threshold [2].
What is the neuroprotective research on GHK-Cu?
Neuroprotection is an emerging, mostly in-vitro and rodent area: a biotinylated GHK-copper complex showed antioxidant and antiglycation protection against amyloid-β/acrolein adducts in cell-free and cell assays [14], consistent with GHK-Cu's copper-handling chemistry — though no human neuroprotection data exist.
Can GHK-Cu cross the blood-brain barrier?
No validated human blood-brain-barrier penetration data exist for GHK-Cu. Rodent cognitive studies reach the CNS by intranasal or intraperitoneal delivery rather than by demonstrating systemic BBB crossing, and the free tripeptide is rapidly cleared by plasma peptidases [6] — so any CNS claim is route-dependent and preclinical.